Cibus (NASDAQ:CBUS) Stock Price Expected to Rise, Jefferies Financial Group Analyst Says

Cibus (NASDAQ:CBUS) had its price objective boosted by equities research analysts at Jefferies Financial Group from $1.90 to $3.00 in a research note issued on Wednesday,Benzinga reports. The firm presently has a “hold” rating on the stock. Jefferies Financial Group’s price target would indicate a potential upside of 7.14% from the stock’s current price.

Several other research firms have also recently issued reports on CBUS. Weiss Ratings restated a “sell (e+)” rating on shares of Cibus in a report on Wednesday, January 21st. Canaccord Genuity Group reiterated a “buy” rating and set a $15.00 target price on shares of Cibus in a research report on Monday, December 8th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $9.00.

Cibus Trading Up 3.3%

Shares of CBUS traded up $0.09 on Wednesday, hitting $2.80. 146,529 shares of the stock traded hands, compared to its average volume of 486,891. Cibus has a 1 year low of $1.09 and a 1 year high of $4.19. The stock’s 50 day moving average is $2.68 and its two-hundred day moving average is $1.93. The firm has a market capitalization of $151.98 million, a P/E ratio of -0.94 and a beta of 1.62. The company has a quick ratio of 0.72, a current ratio of 0.72 and a debt-to-equity ratio of 1.37.

Cibus (NASDAQ:CBUS) last released its earnings results on Tuesday, March 17th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.01. The firm had revenue of $1.06 million during the quarter, compared to analysts’ expectations of $1.64 million. Cibus had a negative net margin of 3,492.30% and a negative return on equity of 174.58%. As a group, sell-side analysts predict that Cibus will post -2.96 earnings per share for the current year.

Hedge Funds Weigh In On Cibus

A number of large investors have recently bought and sold shares of CBUS. Corient Private Wealth LLC acquired a new position in shares of Cibus in the 4th quarter valued at $145,000. PACK Private Wealth LLC acquired a new stake in shares of Cibus during the 4th quarter worth $27,000. BDT Capital Partners LLC raised its position in shares of Cibus by 1,899.7% in the 4th quarter. BDT Capital Partners LLC now owns 63,410 shares of the company’s stock worth $110,000 after buying an additional 60,239 shares during the period. Renaissance Technologies LLC raised its position in shares of Cibus by 74.4% in the 4th quarter. Renaissance Technologies LLC now owns 69,400 shares of the company’s stock worth $121,000 after buying an additional 29,600 shares during the period. Finally, Goldman Sachs Group Inc. boosted its holdings in Cibus by 60.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 52,364 shares of the company’s stock valued at $91,000 after acquiring an additional 19,717 shares during the last quarter. Hedge funds and other institutional investors own 33.81% of the company’s stock.

About Cibus

Cibus, Inc is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company’s platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company’s core business centers on trait development services and licensing partnerships.